No6(2) 2019
Back to the issue
|
DOI 10.37219/2528-8253-2019-6-37 |
Kovtunenko OV, Tymchuk SM, Shportko BV
Analysis of expression of molecular marker KI-67 in patients with laryngeal
cancer for regional metastases and recurrences |
Kovtunenko Alexander Vasilievich
State Institution «Dnipropetrovsk Medical Academy of the Ministry of Health
of Ukraine»
Professor of the Department of Otolaryngology
Doctor of Medical Sciences
Email: lor@dsma.dp.ua
Orchid ID: https://orcid.org/0000-0002-0562-7684
Tymchuk Sergey Nikolaevich
Municipal enterprise «Dnipropetrovsk Regional Clinical Hospital named after
I.I. Mechnikov» Dnipropetrovsk Regional Council
Head of the Department of Otorhinolaryngology No. 2 (oncological)
Doctor of Medical Sciences
Email: sergej_lor@ukr.net
Orchid ID: https://orcid.org/0000-0002-8706-2313
Shportko Bogdan Viktorovich
Municipal enterprise «Dnipropetrovsk Regional Clinical Hospital named after
I.I. Mechnikov» Dnipropetrovsk Regional Council
Department of Otorhinolaryngology No. 2 (oncological)
Otolaryngologist
Email: bogdan.shportko@gmail.com
Orchid ID: https://orcid.org/0000-0002-4242-2784 |
|
Abstract
Background: Laryngeal cancer is a common localization of squamous
cell carcinoma of the head and neck. The main factor influencing the
survival of patients is the presence of regional metastases. The malignant
degeneration of a cell is always accompanied by disruption of the cell
cycle, in particular a sharp increase in proliferative activity. The
molecular marker Ki-67 is used to investigate the proliferative activity of
tumor cells.
Aim of the study: To study the informative content of
immunohistochemical investigation and to determine the expression of the
molecular marker Ki-67 in patients with laryngeal cancer, prior to the
prediction of regional metastasis and relapse.
Materials and Methods: 70 patients with cancer, stage III-IV
(T3-4N0-3M0) clinical group II were under observation. Of these, 39 patients
from the main group were with regional laryngeal cancer metastases, and 31
patients in the comparison group – without revealed regional metastases.
Patients' age ranged from 33 to 74 years. The average age was 61.9 years.
Male patients made up the absolute majority of 99% No = 69. All patients
were histologically diagnosed with squamous cell carcinoma. Monoclonal
antibodies to Ki67 (TermoScientific, USA) were used as the primary molecular
markers. The proliferation index (PI) was rated as low in the range of 0-30%
and as high in more than 30% of positive cells with an intranuclear label.
Results: The study of molecular markers Ki-67 showed its expression
at 69 [60.2; 77.5]% (Me [25%; 75%]) for the squamous cell laryngeal cancer
group, without metastases – 60 [29; 70.5]%, for the group with metastases –
72 [67; 80]% (P <0.001).
In statistical data processing, the AUC value (0.777) was set for Ki-67 for
metastasis and showed an increased degree of expression for laryngeal cancer
metastasis. Ki-67 has a good diagnostic value and can be used as an
additional method for predicting regional laryngeal cancer metastases.
However the practical use of this marker as a prognostic one for determining
the volume of surgery on the lymphatic structures of the neck requires
further investigation.
It should be noted that this study did not reveal the link of Ki-67 AUC
(0.588) with the degree of differentiation of laryngeal cancer and its
recurrence, but more in-depth study of molecular markers in the future may
reveal other patterns of tumor growth and be used in the prognosis and
personalization of treatment.
Conclusion: Expression of Ki-67 allowed to accurately predict tumor
metastasis. A 1% increase in Ki-67 expression resulted in an 8.3% increase
in the chance of tumor metastasis (95% CI - 1.043-1.142), and the age
dependence on metastasis is not reliable.
Determination of expression of Ki-67 does not accurately predict the
possibility of recurrence of laryngeal cancer (p=0.27; AUC (95% CI) – 0.588
(0.414-0.763)) herewith age dependence of chance of a recurrence was not
revealed. |
|
Keywords
laryngeal cancer, metastases, immunohistochemical study, Ki-67. |
|
Reference
- Bai Y, Shao Y, Li H, Xue W, Quan F, Wu S. Ki67 is over expressed in
human laryngeal carcinoma and contributes to the proliferation of HEp2
cells. Oncology Letters. 2016; 12(4): 2641-2647. doi:
10.3892/ol.2016.4980
- Barutзu O, Kara M, Muratlı A, GьзlÑŒ O, Derekцy S. Clinical
significance of Ki-67, c-erbB-2 and E-cadherin expressions in open
partial laryngectomy patients. Kulak Burun Bogaz Ihtisas Dergisi. 2016;
26(5): 283-292. doi:10.5606/kbbihtisas.2016.66592.
- Barnes L, Eveson J W, Richard P, Sidransky D. World Health
Organization Classification of Tumours: pathology and genetics of head
and neck tumours. Lyon, France: IARC Press; 2005. 430 p
- Bonhin RG, de Carvalho GM, Guimarгes AC, Chone CT, Crespo AN, de
Almeida Milani Altemani AM, et al. Histologic correlation of expression
of Ki-67 in squamous cell carcinoma of the glottis according to the
degree of cell differentiation. Brazilian Journal of Otorhinolaryngology.
2014; 80(4): 290-295. doi: 10.1016/j.bjorl.2014.05.016
- Bradford CR, Kumar B, Bellile E, Lee J, Taylor J, D’Silva N et al.
Biomarkers in Advanced Larynx Cancer. Laryngoscope. 2014 Jan; 124(1):
179-87. doi: 10.1002/lary.24245.
- De Bree R, Takes RP, Castelijns JA, Medina JE, Stoeckli SJ, Mancuso
AA, et al. Advances in diagnostic modalities to detect occult lymph node
metastases in head and neck squamous cell carcinoma. Head Neck. 2015
Dec; 37(12): 1829-39.
doi:
10.1002/hed.23814.
- De Vincentiis M, Di Cello P, Censi F, Leopizzi M,
Natalizi S, Sardella B, et al. Immunohistochemical
expression of fatty acid synthase, Ki-67 and p53 in
squamous cell carcinomas of the larynx. The International Journal of Biological Markers. 2008; 23(3):
176-81. doi: 10.1177/172460080802300307.
- Ferlito A, Rinaldo A, Robbins KT, Leemans CR,
Shah JP, Shaha AR, et al. Changing concepts in the surgical management
of the cervical node metastasis. Oral Oncol. 2003 Jul; 39(5): 429-35. doi:
10.1016/s1368-8375(03)00010-1.
- Gioacchini FM, Alicandri-Ciufelli M, Magliulo G,
Rubini C, Presutti L, Re M. The clinical relevance
of Ki-67 expression in laryngeal squamous cell
carcinoma. Eur Arch Otorhinolaryngol. 2015 Jul;
272(7): 1569-76.
doi: 10.1007/s00405-014-3117-0.
- Hamoir M, Ferlito A, Schmitz S, Hanin FX, Thariat J, Weynand B, et al. The role of neck dissection in the setting of chemoradiation therapy for
head and neck squamous cell carcinoma with advanced neck disease. Oral Oncol. 2012; 48(3):
203-10. doi: 10.1016/j.oraloncology.2011.10.015.
- Koontongkaew S. The tumor microenvironment
contribution to development, growth, invasion and
metastasis of head and neck squamous cell carcinomas. J. Cancer. 2013; 4: 66-83. doi:
10.7150/jca.5112
- Kulagin RN. [Molecular prognostic markers of
lymphogenous metastasis of squamous cell carcinoma of the larynx (an immuno-histochemical
study)]. Vestn Otorinolaringol. 2011;(5):11-4. [Article in Russian].
- Li DW, Sun YJ, Sun ZF, Dong P. Involvement of
focal adhesion kinase in cellular proliferation, apoptosis and prognosis of laryngeal squamous
cell carcinoma. J Laryngol Otol. 2012 Nov; 126(11): 1127-33. doi: 10.1017/S0022215112001971.
- Pich A, Chiusa L, Navone R. Prognostic relevance of cell
proliferation in head and neck tumors. Annals of Oncology. 2004; 15(9): 1319-29. doi:
10.1093/annonc/mdh299.
- Re M, Zizzi A, Ferrante L, Stramazzotti D, Goteri
G, Gioacchini FM, et al. p63 and Ki-67 immunostainings in laryngeal squamous cell carcinoma are
related to survival. Eur Arch Otorhinolaryngol.
2014 Jun; 271(6): 1641-51.
doi: 10.1007/s00405-013-2833-1.
- Robbins KT, Ferlito A, Shah JP, Hamoir M, Takes
RP, Strojan P, et al. The evolving role of selective
neck dissection for head and neck squamous cell
carcinoma. Eur Arch Otorhinolaryngol. 2013 Mar;
270(4): 1195-202.
doi: 10.1007/s00405-012-2153-x.
- Vukelic J, Dobrila-Dintinjana R, Dekanic A, Marijic
B, Cubranic A, Braut T. The relevance of assessing
the cell proliferation factor ki-67 in squamous cell
carcinoma of the larynx. Biomed. Res. Int. 2019;
2019: 8142572.
doi: 10.1155/2019/8142572.
|
|